271 related articles for article (PubMed ID: 33419761)
1. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1
Dovedi SJ; Elder MJ; Yang C; Sitnikova SI; Irving L; Hansen A; Hair J; Jones DC; Hasani S; Wang B; Im SA; Tran B; Subramaniam DS; Gainer SD; Vashisht K; Lewis A; Jin X; Kentner S; Mulgrew K; Wang Y; Overstreet MG; Dodgson J; Wu Y; Palazon A; Morrow M; Rainey GJ; Browne GJ; Neal F; Murray TV; Toloczko AD; Dall'Acqua W; Achour I; Freeman DJ; Wilkinson RW; Mazor Y
Cancer Discov; 2021 May; 11(5):1100-1117. PubMed ID: 33419761
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity.
Burton EM; Tawbi HA
Cancer Discov; 2021 May; 11(5):1008-1010. PubMed ID: 33947716
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
Bauché D; Mauze S; Kochel C; Grein J; Sawant A; Zybina Y; Blumenschein W; Yang P; Annamalai L; Yearley JH; Punnonen J; Bowman EP; Chackerian A; Laface D
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127658
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
7. Elevated T cell activation score is associated with improved survival of breast cancer.
Lu L; Bai Y; Wang Z
Breast Cancer Res Treat; 2017 Aug; 164(3):689-696. PubMed ID: 28488141
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
9. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
10. MEDI5752 Suppresses Two Immune Checkpoints.
Cancer Discov; 2022 Jun; 12(6):1402. PubMed ID: 35417536
[TBL] [Abstract][Full Text] [Related]
11. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
12. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
13. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.
Liu JN; Kong XS; Huang T; Wang R; Li W; Chen QF
Front Immunol; 2020; 11():2048. PubMed ID: 33072070
[TBL] [Abstract][Full Text] [Related]
15. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
[TBL] [Abstract][Full Text] [Related]
16. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
Brunner-Weinzierl MC; Rudd CE
Front Immunol; 2018; 9():2737. PubMed ID: 30542345
[TBL] [Abstract][Full Text] [Related]
18. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
19. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
